Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by PlaySafeon Aug 19, 2021 8:07am
169 Views
Post# 33729170

RE:RE:RE:RE:RE:RE:Sad

RE:RE:RE:RE:RE:RE:SadYou are all forgeting about the H2S and Otena's value proposition.  Antibe has demonstrated the GI safety of their drug over other NSAIDs which is the main value of Otena over Naproxen or other NSAIDs.  GI bleeds are a major concern for physicians when prescribing NSAIDs to be taken over a longer periods and NSAIDs are NOT prescribed at all for elderly patientce for fear of GI bleeds. Whether or not 100mg of Otena over 4 weeks cause elevated LTE levels is what we are waiting for to hear about from Antibe.  We also know that the participants that were in the 75mg group did not experience elevated LTE levles.  The question whether or not 75mg can reduce OA pain sufficiently is still to be answerd.  But since Otena has a component of Naproxen then we know that it will for sure have pain releif and in combination wiht H2S wich reduces inflamation there is no doubt that it will reduce pain but to what level we don't know yet.  However, if you can take Otena at 75mg for an extended period of time  to manage OA pain and possibly suplement, if/when needed once in a while with Naproxen then I see this as a viable path forward for the drug and Antibe. Furthermore, Otena at 75mg would be able to be prescribed to the elderly to reduce at least some level of pain whereas today they have no NSAID option.
<< Previous
Bullboard Posts
Next >>